Bio­gen makes an­oth­er bold Alzheimer’s bet, drop­ping $350M up­front to part­ner with genome-edit­ing fo­cused Sang­amo

While the fate of Bio­gen’s res­ur­rect­ed Alzheimer’s drug ad­u­canum­ab re­mains un­cer­tain, the Cam­bridge, MA-based drug­mak­er is join­ing forces with genome edit­ing com­pa­ny Sang­amo Ther­a­peu­tics to de­vel­op ther­a­pies for neu­ro­log­i­cal con­di­tions.

Sang­amo is set to re­ceive a meaty $350 mil­lion up­front in cash and stock and is el­i­gi­ble to re­ceive up to $2.37 bil­lion in mile­stone pay­ments, in ad­di­tion to roy­al­ties. In re­turn, Bio­gen gets the rights to two Sang­amo pre­clin­i­cal com­pounds: ST-501 (for use in tauopathies in­clud­ing Alzheimer’s dis­ease) and ST-502 (for synu­cle­inopathies in­clud­ing Parkin­son’s dis­ease).

“The part­ner­ship rep­re­sents a low­er-cost way to ex­pand its work in neu­ro­log­ic dis­ease,” Cred­it Su­isse’s Evan Seiger­man said in a note, re­fer­ring to Bio­gen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER